Authors
Latest:
Study Shows Gene Expression in Cancerous Bladder Tumors Differs by RaceA new study led by Cedars-Sinai Cancer investigators shows for the first time that gene expression differs by race in patients with high-risk non-muscle-invasive bladder cancer.
Latest:
Dr. Bello on Biomarkers in Follicular LymphomaCeleste Bello, MD, hematologist/oncologist, Moffitt Cancer Center, discusses investigational biomarkers in follicular lymphoma.
Latest:
Dr. Lebbe Discusses Efficacy of Avelumab in Merkel Cell CarcinomaCeleste Lebbe, MD, PhD, Hopital Saint Louis in Paris, discusses the efficacy of avelumab (Bavencio) in patients with stage IV Merkel cell carcinoma.
Latest:
Dr. Higano on the Effectiveness of PARP Inhibitors for Prostate CancerCelestia Higano, MD, professor of medicine and urology at the University of Washington, and a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses the effectiveness of PARP inhibitors for patients with metastatic prostate cancer.
Latest:
Dr. Higano on the Toxicity of Androgen Receptor Inhibitors in CRPCCelestia Higano, MD, FACP, member, Clinical Research Division, Fred Hutchinson Cancer Research Center, professor, Department of Medicine and Urology, University of Washington, Seattle Cancer Care Alliance, discusses the toxicity of androgen receptor inhibitors in castration-resistant prostate cancer.
Latest:
Dr. Higano on Radium-223 for mCRPCCelestia S. Higano, MD, FACP, professor of medicine and urology, University of Washington, discusses radium-223 chloride and its efficacy for patients with metastatic castration-resistant prostate cancer (mCRPC).
Latest:
Dr. Higano on the GETUG-AFU 16 Trial Results in Prostate CancerCelestia S. Higano, MD, discusses the outcomes of the GETUG-AFU 16 and its impact on current practices for prostate cancer.
Latest:
Dr. Higano on the State of Immunotherapy in Prostate CancerCelestia S. Higano, MD, FACP, discusses the state of immunotherapy in prostate cancer.
Latest:
Dr. Rodriguez on Evolving Role of Small Molecules in Multiple MyelomaCesar Rodriguez Valdes, MD, assistant professor of Hematology and Oncology, Wake Forest University Comprehensive Cancer Center, highlights the evolving role of small molecules in multiple myeloma.
Latest:
Dr. Cherington on the Use of Immunotherapy and Targeted Therapy in Lung CancerChad Cherington, MD, discusses the use of immunotherapy and targeted therapy in lung cancer.
Latest:
Dr. Pecot on Selecting Between Available Targeted Therapies in NSCLCChad V. Pecot, MD, discusses selecting between available targeted therapies in RET-, KRAS-, and MET exon 14 skipping–mutant non–small cell lung cancer.
Latest:
Dr. Cheah on Treatment for Nodular Lymphocyte Predominant Hodgkin LymphomaChan Cheah, MD, University of Western Australia, discusses treatment for patients with nodular lymphocyte predominant Hodgkin lymphoma.
Latest:
To Radiation With Love: A Bench-to-Bedside Immunotherapy StoryInvestigators from Montefiore developed a novel combination that has now demonstrated early-stage efficacy in metastatic lung cancer.
Latest:
Dr. Chandra Belani on Atezolizumab in NSCLCChandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses atezolizumab in non-small cell lung cancer (NSCLC).
Latest:
Dr. Andreadis on Antibody-Drug Conjugates in DLBCLCharalambos (Babis) Andreadis, MD, MSCE, discusses the utility of antibody-drugs conjugates in diffuse large B-cell lymphoma.
Latest:
Dr. Leath on Agents Under Investigation in Cervical CancerCharles A. Leath III, MD, gynecologic oncologist at the University of Alabama at Birmingham, discusses agents under investigation in cervical cancer.
Latest:
Dr. Leath Discusses Surgical Cytoreduction in Ovarian CancerCharles A. (Trey) Leath, III, MD, associate professor, UAB School of Medicine, UAB Comprehensive Cancer Center, discusses surgical cytoreduction in ovarian cancer.
Latest:
The Landscape of Chemoprevention in Lung Cancer: A Conversation With Waun K. Hong, MD, PhDOver the past 25 years, multiple lung cancer chemoprevention trials have missed the mark with agents that looked good on paper but lacked the molecular biology support to make a difference.
Latest:
Dr. Catton on Quality Assurance for Radiation Therapy for SarcomaCharles Catton, MD, professor, Department of Radiation Oncology University of Toronto, discusses quality assurance with radiation therapy for patients with sarcoma.
Latest:
Dr. Coombes on Intriguing Results With Celecoxib in Breast CancerCharles Coombes, MD, professor of medical oncology, Imperial College London, discusses surprising results from a recent study examining celecoxib’s impact on breast cancer progression and relapse.
Latest:
Dr. Geyer on Challenges in HER2+ Metastatic Breast Cancer ManagementCharles E. Geyer, Jr, MD, professor of medicine, Virginia Commonwealth University School of Medicine; associate director for clinical research and Harrigan, Haw, Luck Families chair in Cancer Research, Massey Cancer Center, discusses ongoing challenges in the management of patients with metastatic HER2-positive breast cancer.
